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REPORT
Mutations in TOPORS Cause Autosomal Dominant Retinitis
Pigmentosa with Perivascular Retinal Pigment Epithelium Atrophy
Christina F. Chakarova,* Myrto G. Papaioannou,* Hemant Khanna, Irma Lopez, Naushin Waseem,
Amna Shah, Torsten Theis, James Friedman, Cecilia Maubaret, Kinga Bujakowska, Brotati Veraitch,
Mai M. Abd El-Aziz, De Quincy Prescott, Sunil K. Parapuram, Wendy A. Bickmore,
Peter M. G. Munro, Andreas Gal, Christian P. Hamel, Valeria Marigo, Chris P. Ponting,
Bernd Wissinger, Eberhart Zrenner, Karl Matter, Anand Swaroop, Robert K. Koenekoop,
and Shomi S. Bhattacharya
We report mutations in the gene for topoisomerase I–binding RS protein (TOPORS) in patients with autosomal dominant
retinitis pigmentosa (adRP) linked to chromosome 9p21.1 (locus RP31). A positional-cloning approach, together with
the use of bioinformatics, identified TOPORS (comprising three exons and encoding a protein of 1,045 aa) as the gene
responsible for adRP. Mutations that include an insertion and a deletion have been identified in two adRP-affected
families—one French Canadian and one German family, respectively. Interestingly, a distinct phenotype is noted at the
earlier stages of the disease, with an unusual perivascular cuff of retinal pigment epithelium atrophy, which was found
surrounding the superior and inferior arcades in the retina. TOPORS is a RING domain–containing E3 ubiquitin ligase
and localizes in the nucleus in speckled loci that are associated with promyelocytic leukemia bodies. The ubiquitous
nature of TOPORS expression and a lack of mutant protein in patients are highly suggestive of haploinsufficiency, rather
than a dominant negative effect, as the molecular mechanism of the disease and make rescue of the clinical phenotype
amenable to somatic gene therapy.
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Retinitis pigmentosa (RP) is a clinically and genetically
heterogeneous disorder with an incidence of 1 in 3,500,
or a total of 1.8 million people affected worldwide. Af-
fected individuals experience a progressive degeneration
of the photoreceptors, which eventually results in severe
visual impairment. The mode of inheritance of RP can be
autosomal dominant (adRP), autosomal recessive, X linked,
or digenic.1 To date, at least 16 causative genes have been
identified for adRP (RetNet) (MIM numbers 114760,
602225, 607643, 602275, 146690, 604485, 162080, 607301,
607300, 606419, 179605, 180380, 180721, 603937, 607331,
and 607292), and the products of these genes are associ-
ated with photoreceptor structure; cellular function, in-
cluding the phototransduction cascade; or gene expres-
sion, including transcription and mRNA splicing.2
Recently, we reported a new locus for adRP (RP31) in a
three-generation family based in the province of Quebec,
Canada.3 After exclusion of all known loci for adRP, a ge-
nomewide search established positive linkage to a marker
from the short arm of chromosome 9 (LOD score of 6.3
at recombination fraction ). The linked region isqp 0
flanked by markers D9S157 and AFMe153td9 on 9p22-
p21.1, corresponding to a physical distance of 15 Mb.3
Since the previous report,3 17 members with RP from
this family, ranging in age from 8 to 64 years, were clin-
ically reexamined at the Montreal Children’s Hospital Re-
search Institute. Age at onset of symptoms ranged from
10 to 50 years and differed between the generations, and
three affected patients were found to be asymptomatic.
Visual acuities (range 20/20 to finger counting) were main-
tained in most patients, since 16 of 17 had better than
20/40 acuity, and 11 of 17 had 20/20 acuity at the most
recent visit. Visual-field sizes ranged from 10 to 80, and
electroretinography (ERG) abnormalities were highly var-
iable as well, with early rod dysfunction followed by cone
defects. The earliest sign of disease (found in four children)
was an unusual perivascular cuff of retinal pigment epi-
thelium (RPE) atrophy, which was found surrounding the
superior and inferior arcades (fig. 1). This progressed to a
diffuse pigmentary retinopathy with choroidal sclerosis.
Three patients with the disease haplotype were asymp-
tomatic and had completely normal retinal appearance;
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Figure 1. Color photograph of the right eye of a 10-year-old
affected child (IV:3). At this age, a very obvious and unusual
perivascular “cuff” of atrophy (arrows) around the superior and
inferior vascular arcades is visible. The optic disc appears normal
in color, although the retinal arterioles are narrow, and there was
no pigmentary degeneration at this stage. The cuff of RPE atrophy
was found in three other children in this family as well but was
not found in the adults of this pedigree. At a later age, this feature
apparently disappears.
nonetheless, their ERG abnormalities were similar to those
in the symptomatic patients. This phenotype differs sig-
nificantly from the clinical diagnosis associated with the
other 16 published adRP gene defects. A detailed descrip-
tion of the phenotype will be published elsewhere.
Linkage analysis spanning the disease locus on chro-
mosome 9p21 refined the genetic interval to 14 Mb be-
tween markers IVS4-46G (NP_060395.3) and AFMa153td9;
this critical region contains 48 known and 5 novel (hy-
pothetical) genes. The list of genes (in order from telo-
mere to centromere of chromosome 9) that have been
systematically screened includes NP_060395.3, RPS6,
ASAH3L, SLC24A2, MllT3, KIAA1797, NP_001010915.1,
IFNB1, IFNW1, IFNA21, IFNA4, IFNA14, IFNA10,
IFNA17, IFNA5, KLHL9, IFNA6, NP_008831.2, IFNA2,
IFNA8, IFNA1, Q8WTY6, NP_795372.1, MTAP, NSGX,
NP_478102.1, CDKN2A, CDKN2B, DMRTA1, ELAVL2,
TUSC1, NP_079104.2, PLAA, CCDC2, LRRC19, TEK,
NP_065692.1, MOBKL2B, IFNK, NP_659442.2, NP_689783.1,
Q5T776, ACO1, DDX58, TOPORS (MIM 609507), NDUFB6,
TAF1L, and NP_997723.1 (Ensembl). All exons and their
respective acceptor- and donor-splice sites were directly
analyzed from the PCR products with the use of ABI
BigDye terminator cycle sequencing kit v3.1 (Applied Bio-
systems) on an ABI 3100 Genetic Analyzer. Most of the
genes encode proteins with well-documented functions.
From this list of 53 genes, 2 were prioritized for imme-
diate screening because of their specific expression and
known retinal function: the gene encoding retinal cone
Na-CaK-exchanger (SLC24A2 [MIM 609838]), which is
abundantly expressed in cone photoreceptors and retinal
ganglion cells,4 and the gene encoding embryonic-lethal
abnormal visual RNA-binding protein involved in growth,
differentiation, and posttranscriptional gene expression
(ELAVL2 [MIM 601673]), which plays an important role
in RNA processing.5 No disease-causing mutations were
identified in these two genes. We then continued with our
systematic mutation screening of all expressed genes from
the candidate region. Several of the genes contained se-
quence changes that were also identified in healthy un-
related controls, confirming that the variant is benign.
Sequence analysis of one of the genes, TOPORS (MIM
609923, NM_005802), a 13-kb gene with three exons,6
revealed a heterozygous 1-bp insertion (c.2474_2475insA)
in exon 3; this frameshift mutation segregates with the
affected status and is predicted to result in a premature
stop codon (p.Tyr825fs) (fig. 2A and 2B). We also iden-
tified a second TOPORS mutation, a 2-bp deletion
(c.2552_2553delGA) in exon 3 leading to p.Arg851fs, in a
small German family (fig. 2C and 2D). We did not detect
these changes in a control panel of 200 individuals of
white origin. Primer sequences for mutation analysis of
all three exons of TOPORS are listed in table 1. The pres-
ence of two distinct heterozygous frameshift mutations in
two independent families strongly supports the argument
that mutations in TOPORS are responsible for RP31. Se-
quencing of the coding regions of all other genes in the
RP31 critical region revealed only nonpathogenic se-
quence variants. The second TOPORS mutation was iden-
tified as a result of our screening of a panel of 65 unrelated
German patients with adRP attending the Retina Clinic at
University Eye Hospital, Tubingen. On the basis of these
preliminary findings, it is likely that TOPORS mutations
are a rare cause of retinal degeneration.
The TOPORS gene encodes a major transcript of 3.1 kb,
which produces a multidomain protein of 1,045 aa with
an N-terminal RING-type zinc-finger domain (amino
acids 103–141); five stretches enriched in proline, glu-
tamic acid, serine, and threonine (PEST) residues, which
are frequently characteristic of rapidly degraded proteins7;
a bipartite nuclear localization signal; and a region rich
in Arg-Ser (RS)8 (fig. 3A). RT-PCR analysis revealed a broad
tissue expression of TOPORS in human tissues, including
the retina (fig. 3B).
To examine the effect of disease-associated mutations,
we performed immunoblotting of whole lymphoblastoid
cell lysates from both families in affected and unaffected
individuals, using an N-terminus mouse monoclonal TO-
PORS antibody (Abnova). The full-length TOPORS-immu-
noreactive band of 150 kDa is present in the lymphocytes
of control and affected individuals; however, the muta-
tions are predicted to delete 221 aa (∼30 kDa) and 175 aa
(∼25 kDa) from the C-terminus of the protein in the
French Canadian and German families, respectively. As a
result, the truncated protein is expected to have a theo-
retical molecular weight of 120–125 kDa. Our analysis did
not detect the predicted truncated TOPORS-immunoreac-
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Figure 2. Pedigree structure and sequence analysis of TOPORS mutations. A and C, Canadian and German adRP-affected pedigrees,
respectively, used in this study. Affected individuals are shown by blackened symbols, unaffected individuals are identified by unblackened
symbols, and deceased individuals are indicated by a slash (/). Asymptomatic individuals are marked by an asterisk (*). Mutation
segregation is shown on the pedigree as / (normal) or / (affected). B, Electropherogram of the heterozygous mutation,
c.2474_2475insA (p.Tyr825fs), in exon 3 of the TOPORS gene found in the Canadian family. D, Electropherogram of the heterozygous
mutation found in the German family, c.2552_2553delGA (p.Arg851fs). Both mutations were identified after cloning of the amplified
PCR product into pGEMT-Easy vector (Promega).
tive bands in patient lymphocytes, indicating that the mu-
tant protein is relatively unstable (fig. 4). The absence of
the truncated protein in patients from both families sug-
gests haploinsufficiency, rather than a dominant negative
effect, as the molecular basis of the disease.
TOPORS was identified initially in a screen of proteins
that bind to the N-terminus of topoisomerase I and then
as a protein that interacts with p53.6,9 Like other RING
domain–containing proteins, TOPORS is an E3 ubiquitin
ligase with specific E2 enzymes, and it can ubiquitinate
p53.10 It also undergoes modification by the small ubi-
quitin-like modifier SUMO-1.11 It is located in nuclear
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Table 1. Primers Used for PCR Amplification of TOPORS Exons
Exon
Product
Size
(bp)
Primer Sequence (5′r3′)
Temperature
(C)Forward Reverse
1 628 CGTCAGGTTACCGTTGCC ATATTGCATTGCAACTAG 57
2 616 GGCTGAGTACCAGTAAC CACCAATCCACAGGTGCG 61
3a 847 AGTAATGGGTCACTTAAG AAGAACTGTAAGTTCACG 50
3b 901 ATTCCTCAGTTTATGAGAC TATCACCAGAACTGTAAG 48
3c 864 CTTCTGACAGTTCAGATG GAGCTCTGGACAGAGTCC 56
3d 914 TAGCAGTTGGTCCAGAAG TTGTAACTACATCTTTAG 57
3e 997 CAGATCAAGGAGCCTGTCTAG TAAGCTGCTAGCAGTATC 60
Figure 3. Chromosomal location, domain organization, and expression of TOPORS. A, Schematic representation of exon-intron structure
of TOPORS and domain structure of its protein, including the RING-type zinc-finger domain, RS domain, nuclear localization signal
(NLS), lysine-histidine domain, PEST region, N-amino-terminal (N), and carboxyl-terminal (C). Both mutations (p.Tyr825fs and p.Arg851fs)
are shown with asterisks (*). B, RT-PCR analysis of TOPORS transcript in human tissues: PCR was performed with primers selected from
exon 3 (with 28 cycles). A band of 2.69 kb was observed in all the tested QUICK-Clone cDNAs (Clontech) from retina, brain, kidney,
liver, heart, skeletal muscle, pancreas, lung, and placenta. A ubiquitously expressed gene, PGM1, was used as a control.
speckles that closely associate with promyelocytic leuke-
mia nuclear bodies—nuclear compartments that have
been implicated in transcription, DNA repair, viral de-
fense, stress, cell-cycle regulation, proteolysis, and apop-
tosis.12,13 In Drosophila, Topors (dTopors) ubiquitinates and
regulates the activity of the transcriptional repressor
Hairy.14 It also interacts with proteins of the gypsy insu-
lator protein complex, where its influence on insulator
activity has been shown to depend on its ubiquitin ligase
activity.15
TOPORS contains an RS domain, which is implicated
in pre-mRNA splicing. Mutations in three other proteins
involved in mRNA splicing (PRPF3, PRPC8, and PRPF31)
are also associated with RP.16–18 By binding to specific se-
quences on pre-mRNA and interacting with other splicing
factors via their RS domain, SR proteins mediate different
intraspliceosomal contacts, thereby helping in splice-site
selection and spliceosome assembly. Binding of SR pro-
teins to exonic (intronic) splicing enhancers (silencers)
helps in recruitment of U1 snRNP to the 5′ splice site and
U2 snRNP to the branch point sequence.19 However, TO-
PORS nuclear speckles do not colocalize with nuclear splic-
ing speckles that contain other SR proteins—for example,
SC35.11 A recent genomewide survey revealed a large com-
plexity of RS domain–containing proteins in metazoans
with functions not only in pre-mRNA splicing but also in
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Figure 4. TOPORS expression in patient lymphoblastoid cell lines.
Protein extracts from cell lines from one unaffected and two af-
fected individuals from the Canadian and German families with
p.Tyr825fs and p.Arg851fs mutations, respectively, were analyzed
by SDS-PAGE and immunoblotting, with the use of anti-TOPORS
antibody (Abnova). a-tubulin was used as a control. WT p wild
type.
chromatin remodeling, transcription by RNA polymerase
II, and cell-cycle progression. We therefore predict that
TOPORS not only may be involved in mRNA processing
but also may have a more complex array of functions in
mammalian cells.20
It is possible that the process underlying RP31 patho-
genesis might be distinct from those operating in other
forms of adRP where mutations have previously been
identified in structural proteins and in transcription and
splicing factors. Elucidation of its function in retinal pho-
toreceptors and, more important, studies of its expression
in photoreceptors and protein interactions in retina may
provide new insight into the molecular basis of retinal
degenerations.
Finally, as stated above, the lack of mutant TOPORS
protein in patients in the families reported here is highly
suggestive of haploinsufficiency as the molecular basis of
the disease and therefore makes rescue of the disease phe-
notype amenable to somatic gene therapy. Should hap-
loinsufficiency explain the disease mechanism, targeted
increase in the level of the wild-type protein in photo-
receptor cells of patients should lead to rescue of the dis-
ease phenotype. With use of a viral vector (adeno-asso-
ciated virus or lentivirus)–mediated gene-delivery system
and subretinal injection, a functional copy of the gene
can be delivered under the control of photoreceptor-spe-
cific promoters to achieve targeted expression in the ap-
propriate cell type. Somatic-gene-therapy rescue has been
achieved in several animal models of retinal degeneration,
including the rds mouse, and may also prove to be a suc-
cessful approach for this type of adRP.21,22
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